Internal Reference Number: FOI_7437
Date Request Received: 19/09/2023 00:00:00
Date Request Replied To: 06/10/2023 00:00:00
This response was sent via: By Email
Request Summary: Hidradenitis Suppurativa (HS) drugs
Request Category: Private Individuals
| Question Number 1: How many patients were treated at the Trust in the last 3 months for Hidradenitis Suppurativa (HS) with the following biologic drugs: Adalimumab - Humira Adalimumab Biosimilar Bimekizumab Certolizumab Infliximab - Remicade Infliximab Biosimilar Secukinumab Ustekinumab | |
| Answer To Question 1: Adalimumab - Humira - 0 Adalimumab Biosimilar - <5 Bimekizumab - 0 Certolizumab - 0 Infliximab - Remicade - 0 Infliximab Biosimilar - 0 Secukinumab - 0 Ustekinumab - 0 | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of ¾¨Ó㴫ý Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
